

1 ENGROSSED SENATE
2 BILL NO. 1598

By: Rosino of the Senate

3 and

4 Hill of the House

5
6 [insurance - coverage for certain disorder - terms -
7 codification - effective date]
8

9 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

10 SECTION 1. NEW LAW A new section of law to be codified
11 in the Oklahoma Statutes as Section 6060.25 of Title 36, unless
12 there is created a duplication in numbering, reads as follows:

13 A. Every health benefit plan that is issued or renewed after
14 November 1, 2020, shall include coverage for auto-antibody and
15 calcium calmodulin dependent protein kinase II cell-based testing,
16 limited to one testing panel per year, for pediatric autoimmune
17 neuropsychiatric disorders associated with streptococcal or other
18 infections in pediatric acute onset neuropsychiatric syndrome when
19 the covered person has:

20 1. Neuropsychiatric symptoms that do not respond to treatment
21 within forty-five (45) days of first administered treatment; or

22 2. The diagnosis of an infection or illness within the previous
23 five (5) years; and

24 3. Testing has been ordered by:

- a. a physician licensed under either the Oklahoma Allopathic Medical and Surgical Licensure and Supervision Act or the Oklahoma Osteopathic Medicine Act,
- b. an advanced practice registered nurse, as defined in Section 567.3a of Title 59 of the Oklahoma Statutes, or
- c. a physician assistant, as defined in Section 519.2 of Title 59 of the Oklahoma Statutes.

B. A health benefit plan may require prior authorization or any other utilization review to ensure the criteria required by Section A of this section are met.

C. Coverage required under this section shall be subject to a maximum benefit of One Thousand Dollars (\$1,000.00) billing rate per benefit plan year.

D. As used in this section, "health benefit plan" means any plan or arrangement as defined in subsection C of Section 6060.4 of Title 36 of the Oklahoma Statutes, the Oklahoma Employees Insurance Plan and the state Medicaid program.

E. Benefits provided pursuant to subsection A of this section shall not be subject to a deductible, co-payment or coinsurance requirement, regardless of whether the testing provider is within or outside of the network.

1 F. The Insurance Commission shall promulgate rules necessary to
2 implement the provisions of this section.

3 G. In the event the auto-antibody and calcium calmodulin
4 dependent protein Kinase II cell-based testing described in
5 subsection A of this section is not recognized by the American
6 Academy of Pediatrics within five (5) years of the effective date of
7 this act, the provisions of this section shall sunset.

8 SECTION 2. This act shall become effective November 1, 2020.

9 Passed the Senate the 12th day of March, 2020.

10
11 _____
12 Presiding Officer of the Senate

13 Passed the House of Representatives the ____ day of _____,
14 2020.

15
16 _____
17 Presiding Officer of the House
18 of Representatives
19
20
21
22
23
24